Publications by authors named "Eleonora Bono"
Article Synopsis
- - Omalizumab is an effective treatment for chronic spontaneous urticaria (CSU) resistant to antihistamines, but around 10% of patients do not respond to it; this study evaluated its effectiveness and safety over 8 years in 296 patients.
- - Among the patients, 40.4% were early responders, while 8.6% were non-responders; factors like having no inducible urticaria and higher IgE levels were linked to better responses.
- - The study found that omalizumab had a long-term drug survival rate of 53.5%, with most discontinuations related to clinical remission rather than ineffectiveness, indicating that it is generally safe and effective over time
α-gal syndrome (AGS) is caused by the intake of products containing α-gal (galactose-α-1,3-galactose) like mammalian meat. Over the last decade, scientific literature about AGS has been increasing, but the true burden of cases is still unknown [1, 2]. In the USA (University of Virginia Allergy Clinic), the number of confirmed cases of AGS was 24 in 2009 [3] and increased to 34,000 in the entire USA by 2019 [4].
View Article and Find Full Text PDF